Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) shares were unchanged Thursday. The Wexford, Pa.-based biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. The transaction enables Coeptis to further build its pipeline by adding a patented, elegant, and scalable allogeneic immune cell manufacturing platform that aligns with its existing SNAP-CAR and GEAR technologies, increasing the potential for accelerated product development.
As a result of the transaction, Coeptis acquires exclusive rights to two Investigational New Drug (IND) applications and two assets in the Phase 1 clinical trial stage investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections. In addition, Coeptis augments its existing portfolio of cell therapy product candidates with a distinctly scalable allogeneic cellular immunotherapy platform that is being developed to generate and deliver off-the-shelf (no HLA matching), cost effective, on-demand cell therapies to a broad patient population.
Under the transaction, Coeptis paid Deverra approximately $570,000 in cash and issued to Deverra 4,000,000 shares of Coeptis' common stock.
COEP shares ended Wednesday trading at $1.09
